Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Stock Has Consensus Price Target of $18.00 According to Brokerages

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have been assigned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $18.00.

Several research firms have commented on TVRD. HC Wainwright began coverage on Tvardi Therapeutics in a research report on Monday, June 8th. They set a “buy” rating and a $9.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Wednesday, July 8th. Wall Street Zen upgraded Tvardi Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 12th. Piper Sandler upgraded shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a report on Wednesday, July 8th. Finally, UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a report on Wednesday, July 8th.

Tvardi Therapeutics Stock Performance

NASDAQ TVRD opened at $1.06 on Friday. The firm has a 50 day simple moving average of $1.96 and a 200-day simple moving average of $2.75. Tvardi Therapeutics has a one year low of $0.93 and a one year high of $43.65. The firm has a market cap of $14.14 million, a price-to-earnings ratio of -0.38 and a beta of 0.32.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Equities analysts predict that Tvardi Therapeutics will post -2.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Tvardi Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP purchased a new position in shares of Tvardi Therapeutics during the second quarter worth about $63,000. BlackRock Inc. purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at about $181,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at about $34,000. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s approach is designed to address tumor growth, immune suppression and resistance to existing therapies by selectively targeting STAT3, a protein involved in cancer progression.

Tvardi’s lead product candidate is TTI-101, an orally administered small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors.